GlassScriptPhysician profile
Maribeth Maney
NPI 1619260304
$5,792.03
in general payments reported to CMS, 2019-2025
34 companies · $1,629 in 2025
The $1,629 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $666 · 2022: $736 · 2023: $1,470 · 2024: $1,290 · 2025: $1,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,203 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,202.65 |
| Education | $186.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $849.00 | 2021-2025 | Calquence, Imfinzi |
| Genentech USA, INC. | $632.80 | 2021-2025 | Phesgo, Tecentriq, Perjeta |
| Merck Sharp & Dohme LLC | $595.78 | 2023-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Incyte Corporation | $581.36 | 2023-2025 | Jakafi, Monjuvi, Jakafi |
| Lilly USA, LLC | $405.93 | 2021-2025 | Verzenio |
| Janssen Biotech, INC. | $323.85 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Daiichi Sankyo INC. | $271.82 | 2024-2025 | Enhertu, Datroway, Vanflyta |
| E.R. Squibb & Sons, L.L.C. | $180.44 | 2021-2025 | Pomalyst, Eliquis |
| Astellas Pharma US INC | $146.54 | 2022-2024 | Vyloy |
| Novartis Pharmaceuticals Corporation | $146.17 | 2024-2025 | |
| Amgen INC. | $145.60 | 2021-2023 | Lumakras |
| Abbvie INC. | $132.18 | 2022-2025 | |
| Coherus Oncology, INC. | $125.05 | 2021 | |
| Eisai INC. | $120.18 | 2023 | |
| Genzyme Corporation | $118.78 | 2023-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $114.38 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.01 | 2024 | Fruzaqla |
| Bayer Healthcare Pharmaceuticals INC. | $95.84 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $92.82 | 2022 | |
| Jazz Pharmaceuticals INC. | $73.04 | 2025 | |
| Adaptive Biotechnologies Corporation | $68.03 | 2023-2024 | Clonoseq |
| G1 Therapeutics, INC. | $66.86 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $64.35 | 2024-2025 | Libtayo |
| Seagen INC. | $59.47 | 2022 | |
| Beone Medicines USA, INC. | $54.53 | 2025 | Brukinsa |
| Celgene Corporation | $34.98 | 2023 | Pomalyst |
| Beigene USA, INC. | $33.07 | 2025 | Tevimbra |
| Shorla Oncology INC. | $28.88 | 2025 | |
| Blueprint Medicines Corporation | $27.37 | 2025 | Ayvakit |
| Tersera Therapeutics LLC | $23.63 | 2021 | |
| Gilead Sciences, INC. | $22.15 | 2025 | Trodelvy |
| Array Biopharma INC | $20.68 | 2025 | Lorbrena |
| Ipsen Biopharmaceuticals, INC | $20.00 | 2025 | Onivyde |
| Karyopharm Therapeutics INC. | $13.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maribeth Maney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.